1178

PROMISING EFFICACY OF SMALL MOLECULES AND BIOLOGICALS FOR MICROSCOPIC COLITIS: RESULTS FROM A LARGE REAL-LIFE MULTICENTER COHORT

Date
May 21, 2024

Background
Microscopic colitis (MC) is a chronic inflammatory condition of the colon, resulting in an impaired quality of life due to debilitating watery diarrhea. First-line therapy consists of budesonide, though a subset of patients is refractory or becomes budesonide- dependent. Evidence for the efficacy of biologicals or small molecules in MC is sparse and limited to small case series. Hence, we aimed to generate more real-life efficacy data.

Methods
This retrospective series was collected as part of the CONFER project by ECCO and supported by the European Microscopic Colitis Group (EMCG). Cases of MC patients treated with advanced therapies were included through a standardised collection form. Clinical response was defined as a 50% reduction in stool frequency (SF); clinical remission was defined according to the Hjortswang criteria as < 3 stools/day or < 1 watery stool/day.

Results
Ninety-nine patients were identified (Table 1), of whom all but one were previously treated with budesonide. Reasons for budesonide discontinuation included primary non-response (PNR, 16.3%), refractory disease (34.7%), budesonide dependency (38.8%), or adverse events (AE, 10.2%). In total, 165 treatment cycles with advanced therapy (47 IFX, 40 ADA, 47 VDZ, 10 UST, 14 JAK inhibitors, 7 other) were reported. First-line advanced therapies included mainly anti-TNF (76.8%) and VDZ (20.2%) (Figure 1A). Patients were exposed to anti-TNF therapy for a median of 1.4 [0.5-3.1] years, with a significant drop in SF after induction (p<0.001), resulting in 50.0% clinical remission (Figure 1B). However, 63.0% ultimately discontinued anti-TNF therapy, mainly due to PNR (37.9%), loss-of-response (LOR, 36.2%) or AE (20.7%). VDZ induced 46.8% clinical remission, reflected in a significant drop in SF (p<0.001). Though, a 59.6% discontinuation rate was observed after a median 0.6 [0.3-1.3] years, mainly due to PNR (63.0%) and LOR (22.2%). Similarly, for UST a 40.0% clinical remission rate was accompanied by 60.0% therapy withdrawal, primarily due to PNR (83.3%). In contrast, JAK inhibition resulted in 78.6% clinical remission, with a substantial drop in SF (p=0.002) and 21.4% discontinuation rate after a median exposure of 0.6 [0.3-1.6] years.

Conclusion
Almost all advanced therapies are used in budesonide refractory or dependent MC, with anti-TNF agents the most often used first-line options. However, anti-TNF discontinuation is frequent due to lack/loss of efficacy. VDZ and UST could be alternatives, but also have a substantial discontinuation rate. In this retrospective series, the small number (n=14) of JAK inhibitor treated patients had the highest remission rate, suggesting further research on the role of JAK inhibitors in MC.
<b>Figure 1</b><br /> <br /> Figure 1A: Advanced therapies used to treat MC patients, with a split by 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup> or 4<sup>th</sup> line per mechanism of action.<br />  <br />  <br /> Figure 1B: Clinical response and remission rates after induction per mechanism of action.  <div id=
"/>

Figure 1

Figure 1A: Advanced therapies used to treat MC patients, with a split by 1st, 2nd, 3rd or 4th line per mechanism of action.


Figure 1B: Clinical response and remission rates after induction per mechanism of action.

<b>Table 1: </b>Baseline characteristics of all included patients  <div id=
"/>

Table 1: Baseline characteristics of all included patients


Tracks

Related Products

Thumbnail for NEUTROPHIL EXTRACELLULAR TRAPS ENHANCE PROFIBROTIC ACTIVITY OF INTESTINAL FIBROBLASTS IN CROHN’S DISEASE THROUGH TLR2/NF-KB PATHWAY
NEUTROPHIL EXTRACELLULAR TRAPS ENHANCE PROFIBROTIC ACTIVITY OF INTESTINAL FIBROBLASTS IN CROHN’S DISEASE THROUGH TLR2/NF-KB PATHWAY
BACKGROUND: Neutrophil extracellular traps (NETs) consist of DNA filaments and cytoplasmic protein granules, extruded by neutrophils after PAD4-dependent activation…
Thumbnail for EXPOSURE TO AN INFLAMMATORY PRENATAL ENVIRONMENT AND THE RISK OF INFLAMMATORY BOWEL DISEASE IN THE OFFSPRING: A POPULATION-BASED COHORT STUDY
EXPOSURE TO AN INFLAMMATORY PRENATAL ENVIRONMENT AND THE RISK OF INFLAMMATORY BOWEL DISEASE IN THE OFFSPRING: A POPULATION-BASED COHORT STUDY
The strongest independent risk factor for developing inflammatory bowel disease (IBD) is a family history with IBD. The early life, including the intra-uterine period, is critical for immune system maturation and therefore, exposures during early life can influence IBD risk…
Thumbnail for DISABILITY IN CROHN'S DISEASE PATIENTS AT DIAGNOSIS: FINDINGS FROM THE CROCO (CROHN'S DISEASE COHORT) STUDY
DISABILITY IN CROHN'S DISEASE PATIENTS AT DIAGNOSIS: FINDINGS FROM THE CROCO (CROHN'S DISEASE COHORT) STUDY
BACKGROUND: Crohn's disease (CD) can lead to progressive bowel damage and disability. Disability has been proposed by the SPIRIT-IOIBD consensus as an endpoint in disease-modification trials. Despite this, there is scarce data on disability at CD diagnosis…
Thumbnail for FAECAL MICROBIOTA TRANSPLANTATION IN ACTIVE ULCERATIVE COLITIS: INSIGHTS FROM A RANDOMIZED CONTROLLED TRIAL HALTED FOR FUTILITY
FAECAL MICROBIOTA TRANSPLANTATION IN ACTIVE ULCERATIVE COLITIS: INSIGHTS FROM A RANDOMIZED CONTROLLED TRIAL HALTED FOR FUTILITY
INTRO/BACKGROUND Rigorous donor preselection on microbiota level, strict anaerobic processing, and repeated FMT administration were hypothesized to improve FMT outcomes for induction of remission in UC in the RESTORE-UC trial, for which we here report on the clinical results and observed microbial…